1. What's New in Dyslipidemia?

3. Overview

4. LDL-C vs CV Events Secondary Prevention Studies

5. High- vs Low-Dose Statin

6. The Statin Hypothesis Low vs High Dose

7. LDL-C Level vs Statin Intensity

8. Lipoprotein Abnormalities in T2D

9. Lipoprotein Abnormalities in T2D (cont)

11. T2D as a CVD Risk Equivalent

12. The Role of Statins 2013 ACC/AHA Guidelines

13. 2013 ACC/AHA Cholesterol Guidelines 4 Statin Benefit Groups Identified

14. 2014 NLA Criteria for Treatment Initiation According to Risk

15. 2016 Consensus Statement From ACC/AHA and NLA

16. Intensity of Statin Treatment

17. Role of Metabolic Syndrome

18. Statin Nonadherence and Intolerance

19. Statin Discontinuation After ACS Clinical Consequences

20. Statin Discontinuation in RCTs

21. Statin Adherence in Registry Databases

22. Keep in Mind…

23. Issues With Recommendations Based on Statin Intensity

24. Approaches to Lipid Treatment in T2D 2016 AACE/ACE Algorithm

26. Role of PCSK9 Inhibitors

27. ODYSSEY LONG TERM Alirocumab 150 mg vs Placebo 2:1

28. ODYSSEY LONG TERM (cont)

29. OSLER Evolocumab + Standard Therapy vs Standard Therapy Alone 2:1

31. ODYSSEY LONG TERM AEs by Achieved LDL-C

34. GAUSS-2 and ODYSSEY ALTERNATIVE PCSK9 Inhibitors Well Tolerated by Statin-intolerant Patients

35. Incorporating PCSK9 Inhibitors Into Endocrinology Practice

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)